Korean biosimilars make inroads into Europe
[THE INVESTOR] Propelled by Samsung Bioepis and Celltrion, South Korean biopharmaceutical companies are gaining a foothold in Europe with their biosimilars, cheaper copycat versions of biologics. Celltrion’s Remsima — biosimilar replication of rheumatoid arthritis treatment drug Remicade — and Samsung Bioepis’ Benepali — biosimilar copy of Amgen’s rheumatoid arthritis treatment Enbrel – along with Flixabi, another Remicade biosimilar, are already selling in Europe, one of the world’ largest market for such drugs. Three other biosimilars are awaiting permission from the European [...]